^
Association details:
Biomarker:CD47 overexpression
Cancer:Glioblastoma
Drug:VT1021 (TSP1 stimulant)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

374 A first-in-human Phase 1/2 open label trial evaluating the safety, pharmacology, and preliminary efficacy of VT1021 in subjects with advanced solid tumors

Published date:
11/09/2020
Excerpt:
...VT1021 has demonstrated activities in reprogramming the TME which resulted in a high disease control rate in subjects with tumors expressing both high CD36 and high CD47.
DOI:
10.1136/jitc-2020-SITC2020.0374
Trial ID: